Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              ReiThera

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ITALY Italy

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based COVID-19 Vaccine

              Contact the Supplier

              Lead Product(s): Adenoviral vector-based vaccine

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Univercells

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 23, 2020

              Details:

              The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.

              Takis Biotech

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ITALY Italy

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-clinical Models

              Contact the Supplier

              Lead Product(s): Linear DNA vaccine

              Therapeutic Area: Infections and Infectious Diseases

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 18, 2020

              Details:

              The vaccine is one of four PCR-produced (polymerase chain reaction vaccine) linear DNA vaccine candidates under joint development by Takis Biotech and Applied DNA.

              PharmaCompass__DigitalAd